Source comparison
SS-31 Dosage Protocol: Comparison of Administration Methods
Subcutaneous bolus (once daily) 0.5–1mg/kg ~85% 3.5 hours 2–4 hours to peak Acute injury models, short-term studies Simplest administration but produces peak-trough fluctuation; acceptable for protocols under 7 days Subcutaneous bolus (twice daily) 0.25–0.5mg/
This comparison does not assign a generated winner or score.
- Subcutaneous bolus (once daily)
- 0.5–1mg/kg
- ~85%
- 3.5 hours
- 2–4 hours to peak
- Acute injury models, short-term studies
- Simplest administration but produces peak-trough fluctuation; acceptable for protocols under 7 days
- Subcutaneous bolus (twice daily)
- 0.25–0.5mg/kg per dose
- Chronic mitochondrial dysfunction, neurodegeneration models
- Maintains more stable tissue levels; recommended for protocols over 14 days where consistent mitochondrial support is required
- Intravenous bolus
- 0.5–0.75mg/kg
- ~100%
- 1–2 hours to peak
- Cardiac ischemia-reperfusion, acute oxidative stress
- Fastest tissue delivery; ideal when timing relative to injury is critical (e.g., 10 min pre-ischemia)
- Continuous infusion (osmotic pump)
- 0.6–1mg/kg/day total
- N/A (steady state)
- Steady state by 24h
- Multi-week studies, models requiring stable mitochondrial environment
- Eliminates peak-trough variation entirely; highest consistency but requires surgical pump placement